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Introduction {#acn3537-sec-0005}
============

Late‐onset Alzheimer\'s disease (LOAD) is the most common form of dementia in older adults, it lacks an effective treatment and represents an enormous societal burden. The disease is characterized by progressive deterioration of memory and cognitive functions, leading to loss of autonomy and ultimately requiring full‐time medical care. Pathologically, LOAD is defined by severe neuronal loss, aggregation of amyloid *β* (A*β*) in extracellular senile plaques, and formation of intra‐neuronal neurofibrillary tangles consisting of hyper‐phosphorylated tau protein.

Over the past decade, genetic research in LOAD has been dominated by genome‐wide association studies (GWAS), a hypothesis‐free scan of the genome using dense genotyping arrays based on common variants (single nucleotide polymorphisms, SNPs). Several genes within LOAD susceptibility loci cluster in specific pathways,[1](#acn3537-bib-0001){ref-type="ref"}, [2](#acn3537-bib-0002){ref-type="ref"}, [3](#acn3537-bib-0003){ref-type="ref"}, [4](#acn3537-bib-0004){ref-type="ref"}, [5](#acn3537-bib-0005){ref-type="ref"}, [6](#acn3537-bib-0006){ref-type="ref"} including amyloid processing, oxidative stress and immune or inflammatory pathways. Collectively, GWAS demonstrates that apart from the strongest risk factor, *APOE‐ε4* a large number of loci with modest effect size also contribute to LOAD risk. Common variants identified through GWAS may not have functional consequences, simply reflecting linkage disequilibrium with the unobserved causal variants. It is also possible that these causal variants are rare and have large effects, such as *TREM2,* [7](#acn3537-bib-0007){ref-type="ref"}, [8](#acn3537-bib-0008){ref-type="ref"}, [9](#acn3537-bib-0009){ref-type="ref"}, [10](#acn3537-bib-0010){ref-type="ref"}, [11](#acn3537-bib-0011){ref-type="ref"}, [12](#acn3537-bib-0012){ref-type="ref"}, [13](#acn3537-bib-0013){ref-type="ref"} and are not covered by commercially available GWAS platforms. In fact, putatively damaging variants have already been identified (for example *TREM2*,*SORL1,* and *ABCA7*) in some of these LOAD susceptibility loci, advancing our understanding of disease risk.[14](#acn3537-bib-0014){ref-type="ref"}, [15](#acn3537-bib-0015){ref-type="ref"}, [16](#acn3537-bib-0016){ref-type="ref"}

Whole genome sequencing (WGS) provides a comprehensive and detailed investigation of human genetic variation allowing interrogation of coding and noncoding regions of the genome. Increasingly, WGS studies have provided the strongest evidence that rare genetic variants can have large cumulative effects on human diseases.[17](#acn3537-bib-0017){ref-type="ref"}, [18](#acn3537-bib-0018){ref-type="ref"}, [19](#acn3537-bib-0019){ref-type="ref"}, [20](#acn3537-bib-0020){ref-type="ref"} Family‐based studies represent an implicit enrichment strategy for identifying rare variants.[21](#acn3537-bib-0021){ref-type="ref"} Transmission of variants from parents to offspring maximizes the chance that multiple copies of rare variants exist in the pedigree. Moreover, compared with analyses using unrelated samples, sequencing in families provides data concerning identical‐by‐descent or sharing among relatives, greatly reducing false positives and permitting detection of sequencing errors, while facilitating the identification of alleles that cause genetic disorders.[22](#acn3537-bib-0022){ref-type="ref"}, [23](#acn3537-bib-0023){ref-type="ref"}

In the current report, we focused on Caribbean Hispanic families multiply affected by LOAD. The frequency of LOAD among multiplex families from the Dominican Republic is known to be significantly higher (5‐fold) than expected for similarly aged individuals in a non‐Hispanic white population from the United States.[24](#acn3537-bib-0024){ref-type="ref"} Furthermore, we found that a moderate degree of inbreeding was present and a predictor of LOAD risk in this population.[25](#acn3537-bib-0025){ref-type="ref"} As part of the national Alzheimer\'s Disease Sequencing Project (ADSP), we identified several chromosomal regions with strong evidence for linkage in Caribbean Hispanic families with multiple LOAD cases.[26](#acn3537-bib-0026){ref-type="ref"} In the present study, we used WGS data (Data [S1](#acn3537-sup-0001){ref-type="supplementary-material"}) from 67 families as discovery to detect rare variants in previously identified linkage regions and in previously reported LOAD candidate genes. Genotyping in additional WGS on additional 47 Caucasian families were used to replicate the findings from the CH families.

Material and Methods {#acn3537-sec-0006}
====================

Family characteristics {#acn3537-sec-0007}
----------------------

All participants (Table [1](#acn3537-tbl-0001){ref-type="table-wrap"}) were recruited after providing informed consent and with approval by the relevant institutional review boards both in the United States and in the Dominican Republic. Patients, unaffected family members and healthy unrelated controls were required to have had standard neuropsychological tests and neurological examinations to verify their clinical status and diagnosis. Most individuals have been evaluated on multiple occasions over the past 10 years. Families in which patients had known early‐onset disease mutations in *APP*,*PSEN1*,*PSEN2*,*GRN*, or *MAPT* were excluded from this analysis to increase power of discovery variants predisposing to LOAD. All selected probands came from families with three or more affected individuals recruited in the Dominican Republic and New York. Recruitment for this family study began in 1998, and was restricted to Caribbean Hispanics,[27](#acn3537-bib-0027){ref-type="ref"}, [28](#acn3537-bib-0028){ref-type="ref"} predominately from the Dominican Republic. As a part of the ADSP, a set of 67 CH families and 47 Caucasian families were selected for whole genome sequencing from approximately 1400 families reviewed. Selection was based on the number of affected individuals, the number of generations affected, age at onset of clinical symptoms, and presence of *APOEε4* alleles.[29](#acn3537-bib-0029){ref-type="ref"}

###### 

Demographics of the Caribbean‐Hispanic families and case--control cohorts used in WGS and validation genotyping

  ---------------------------------------------------- ---------------
  Pedigrees Sequenced in ADSP discovery                
  Number of pedigrees                                  67
  Total number of subjects sampled                     860
  Average subjects sampled per pedigree                12.84 ± 7.28
  Total number of subjects sequenced                   351
  Average samples sequenced in each pedigree           5.24 ± 1.67
  Affected                                             302
  Unaffected                                           49
  Average affected per pedigree                        7.42 ± 3.61
  Age (sequenced individuals)                          73.02 ± 10.0
  Women (%)                                            58.72
  APOE                                                 17.03%
  Additional pedigrees used in validation genotyping   
  Number of pedigrees                                  48
  Total number of subjects sampled                     404
  Average subjects sampled per pedigree                8.41 ± 4.8
  Average affected per pedigree                        5.08 ± 2.3
  Age                                                  70.76 ± 10.11
  Women (%)                                            65
  APOE                                                 29.90%
  Unrelated case--control set                          
  Total number of subjects sampled                     450
  No of affected individuals                           152
  Age (affecteds)                                      85.5 ± 6.5
  Age                                                  79.3 ± 6.7
  Women (%)                                            68.7
  APOE                                                 12.80%
  ---------------------------------------------------- ---------------
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Whole Genome Sequence analysis of GWAS linkage peaks {#acn3537-sec-0008}
----------------------------------------------------

Details about WGS methodology and variant calling pipelines can be found in Data [S1](#acn3537-sup-0001){ref-type="supplementary-material"}. Three regions demonstrating linkage previously identified[26](#acn3537-bib-0026){ref-type="ref"} using GWAS data were prioritized for WGS data analysis. Results from genome‐wide linkage analysis revealed a strong linkage signal (HLOD = 3.6) on chromosomal region 3q29.[26](#acn3537-bib-0026){ref-type="ref"} We previously reported microsatellite linkage analyses in this region as strongly associated with LOAD in Caribbean Hispanics,[30](#acn3537-bib-0030){ref-type="ref"} including a single family that achieved a LOD score of 1.28. WGS data was generated for four of the family members with LOAD. Analysis of the WGS data was limited to an approximate 2 Mb region encompassing the 1‐LOD interval around linkage peak (3q29: 197,052,973 bp--199,212,658 bp). We also selected two chromosomal regions where we observed genome‐wide significant linkage and association signals across the families: 7p14.3 and 11q12.3.[26](#acn3537-bib-0026){ref-type="ref"} Annotation of the identified variants in these linkage regions was performed using the ANNOVAR software.[31](#acn3537-bib-0031){ref-type="ref"}

Whole genome sequence variants prioritization {#acn3537-sec-0009}
---------------------------------------------

### Consensus linkage regions {#acn3537-sec-0010}

We followed a principled filtering strategy (Fig. [1](#acn3537-fig-0001){ref-type="fig"}, Table [S4](#acn3537-sup-0002){ref-type="supplementary-material"}) to test the segregation of rare variants with LOAD status in the three linkage regions: 7p14.3 and 11q12.3 and 3q29 (Table [S6](#acn3537-sup-0002){ref-type="supplementary-material"}). The first criterion used to prioritize the identified variants was based on familial segregation of cases. We required that at least 75% of the patients with LOAD and WGS data in the families were carriers. Additionally we also prioritized variants that were observed in at least five affected individuals in multiple Caribbean Hispanic families.

![Filtering strategy to prioritize variants for follow‐up analyses in the validation sample.](ACN3-5-406-g001){#acn3537-fig-0001}

We filtered variants with minor allele frequency (MAF) of less than 0.10 in the ADSP families and with an MAF of 0.02 in Caucasian and African American populations in ExAC database (for exonic variants)[32](#acn3537-bib-0032){ref-type="ref"} and 1000 genomes project (for intronic and intergenic variants)[33](#acn3537-bib-0033){ref-type="ref"} to restrict our analyses to rare variants in the population. Functional annotations were also used as filtering strategy, that is, variants were analyzed in order of increasing priority: exonic, inter‐genic, intronic and others (non‐coding RNA, 3′/5′ UTR, upstream/downstream gene). We also included any intronic or intergenic variants with a Combined Annotation Dependent Depletion (CADD)[34](#acn3537-bib-0034){ref-type="ref"} score of greater than 30 to include highly conserved and putative non‐exonic regulatory variants in the analyses. Further criteria for variant prioritization included, additional LOAD patients from different families carrying the variant and that the variant was either not present or present in very low frequency in the non‐demented family members.

### Follow‐up genotyping validation {#acn3537-sec-0011}

To confirm putative variants that segregated in 67 discovery families and candidate GWAS loci, we genotyped all of the family members in the discovery families, an additional 48 families and unrelated, unaffected controls of the same ancestry and age (Table [1](#acn3537-tbl-0001){ref-type="table-wrap"}). The validation cohort consisted of Caribbean Hispanic individuals from 115 multiplex families and 450 unrelated cases and controls from the same ethnic background (Table [1](#acn3537-tbl-0001){ref-type="table-wrap"}). Population allele frequencies for novel variants were estimated from unaffected persons in the Caribbean Hispanic population from samples/families that we have amassed over 15 years. Genotypes were generated using the KASP^TM^ genotyping technology which uses allele‐specific polymerase chain reaction for accurate calling of single nucleotide variants (SNVs) and indels.[35](#acn3537-bib-0035){ref-type="ref"}

### Single variant association analyses {#acn3537-sec-0012}

SNV genetic associations were restricted to individuals 60 years of age or older and were tested using General Linear Models in generalized estimating equations (GEE) to adjust for familial correlation in the data. The family ID was used as a repeat measure to account for correlation in the genotype data within family members. All analyses were adjusted for sex, age at last evaluation, education, *APOE‐ε4* genotype and the first ten principal components.

### LOAD GWAS and candidate loci {#acn3537-sec-0013}

We tested genes associated with LOAD in large GWAS studies with multiple replication reports. We also included known early‐onset AD genes and genes implicated in earlier sequencing efforts in LOAD.[1](#acn3537-bib-0001){ref-type="ref"}, [2](#acn3537-bib-0002){ref-type="ref"}, [3](#acn3537-bib-0003){ref-type="ref"}, [4](#acn3537-bib-0004){ref-type="ref"}, [5](#acn3537-bib-0005){ref-type="ref"}, [6](#acn3537-bib-0006){ref-type="ref"}, [8](#acn3537-bib-0008){ref-type="ref"}, [9](#acn3537-bib-0009){ref-type="ref"}, [10](#acn3537-bib-0010){ref-type="ref"}, [11](#acn3537-bib-0011){ref-type="ref"}, [12](#acn3537-bib-0012){ref-type="ref"}, [13](#acn3537-bib-0013){ref-type="ref"}, [14](#acn3537-bib-0014){ref-type="ref"}, [15](#acn3537-bib-0015){ref-type="ref"}, [16](#acn3537-bib-0016){ref-type="ref"} Candidate genes evaluated included: *APP, PSEN1, PSEN2, GRN, MAPT, TREM2, PLD3, APOE, ABCA7, SORL1, CR1, BIN1, CD2AP, EPHA1, CLU, MS4A6A, PICALM, CD33, HLA‐DRB5, HLA‐DRB1, PTK2B, SLC24A4, RIN3, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2, CASS4, TREML2, and AKAP9*.

### Gene‐based association analyses {#acn3537-sec-0014}

Gene‐based F‐SKAT[36](#acn3537-bib-0036){ref-type="ref"} analyses were conducted for genes in the three consensus linkage regions. The F‐SKAT test was restricted to variants defined as exonic and rare (\<2% in Europeans, African Americans and overall in the ExAC database). To define a testable‐set, we used two sets of variants in the gene‐based test based on functional annotation: (1) Stop‐loss, stop gain and missense damaging variants (as defined by SIFT[37](#acn3537-bib-0037){ref-type="ref"} or PolyPhen[38](#acn3537-bib-0038){ref-type="ref"}) and (2) including all non‐synonymous variants. We also tested gene‐sets that included both loss of function variants and variants that had a high CADD score (\>30). The CADD score filter captures putatively non‐functional variants in the non‐coding regions. For most genes (Table [S5](#acn3537-sup-0002){ref-type="supplementary-material"}), we did not observe variants in non‐coding regions with a high CADD score. In addition functional characterization of GWAS loci have indicated that cis‐regulation is a common mechanism underlying these associations.[39](#acn3537-bib-0039){ref-type="ref"} The most frequent elements affected are transcriptional enhancers and silencers that regulate transcription through long‐range interactions, typically located more than 1Kb from their target genes. Therefore, to examine the top GWAS signals,[4](#acn3537-bib-0004){ref-type="ref"} we have considered a chromosomal region of 1 Mb upstream and 1 Mb downstream the reported GWAS loci. We conducted F‐SKAT analyses of genes within ±1 Mb encompassing the reported LOAD‐GWAS SNPs. Each gene was independently assessed for association with LOAD using F‐SKAT with the modified R code to adjust for family structure. We tested models of association also adjusting for (1) age, sex, population substructure, ancestry proportions for African‐American and native American ancestry (Data [S1](#acn3537-sup-0001){ref-type="supplementary-material"}) and (2) including *APOE‐ε4* dosage with other covariates. Analyses were subsequently repeated adjusting for the possible effect of the reported GWAS SNP to assess the additional contribution of rare variants in conferring LOAD risk. We also conducted region‐based FSKAT test combining variants from all the genes in the 7p14.3 and 11q12.3 regions to assess the joint burden of all variants together in the region.

Results {#acn3537-sec-0015}
=======

Families {#acn3537-sec-0016}
--------

As detailed in Table [1](#acn3537-tbl-0001){ref-type="table-wrap"}, 67 Caribbean‐Hispanic families underwent WGS. The families consisted of 351 individuals (302 individuals with LOAD and 49 unaffected family members) with average age of 73.02 ± 10 years, 59% were women. Seventeen percent were carriers of APOE‐*ε*4 allele. On average, approximately five individuals were sequenced within each of the families. For validation genotyping, we genotyped all the members of the 67 families, an additional 48 Hispanic families and an independent elderly case control cohort of the same ethnic background. The additional 48 Hispanic families had similar characteristics to the discovery families (Table [1](#acn3537-tbl-0001){ref-type="table-wrap"}). These families also had, on average, five affected individuals, but had a higher frequency for the *APOE ε4* allele (29.9%).

Linkage region in a single Caribbean‐Hispanic family at 3q29 {#acn3537-sec-0017}
------------------------------------------------------------

After applying quality control metrics, we identified a total of 6551 sequence variants under the 3q29 linkage peak. Applying the filters in the prioritization pipeline, we identified 11 rare SNVs: six intronic and five inter‐genic variants. The 11 identified SNVs were genotyped in 1,720 Caribbean Hispanic unrelated individuals. The strongest association with LOAD (*β* = 0.83, SE = 0.45, *P* = 0.064) was found for an intronic variant rs186972238 in the *LRCH3* gene. A complex pattern of inheritance with incomplete penetrance emerged when the variant segregation pattern was evaluated within each of these families.

Locus 7q14.3 {#acn3537-sec-0018}
------------

A total of 35,376 high quality SNVs were observed in 67 families from the WGS experiment and subsequent QC, of which 26,654 SNVs were observed a frequency of \<0.10 in the ADSP families. Applying the filtering criteria described above (Fig. [1](#acn3537-fig-0001){ref-type="fig"}), we observed 12 non‐synonymous and one synonymous mutation that were observed in at least two affected individuals and absent in unaffected members (Table [S1](#acn3537-sup-0002){ref-type="supplementary-material"}).

Locus 11q12.3 {#acn3537-sec-0019}
-------------

A total of 19,106 SNVs were observed in the 11q12.3 linkage regions in the 67 ADSP families of which 149 SNVs were putatively damaging (stop‐loss, stop‐gain or damaging classified by SIFT or PolyPhen) and novel or rare (Fig. [1](#acn3537-fig-0001){ref-type="fig"}). Forty variants were observed to be perfectly or imperfectly segregating in at least one family. Remarkably, p. V707I in *TMEM132A* was observed in two families with complete segregation in one family. (Table [S2](#acn3537-sup-0002){ref-type="supplementary-material"})

Analyses of loci under linkage peaks {#acn3537-sec-0020}
------------------------------------

We selected 14 variants under the linkage peaks (10 from 11q12.3 and 4 from 7q14.3) for follow‐up genotyping in additional family members and unrelated controls. We chose variants that fulfilled at least one of the following criteria: (1) variants observed in two or more Caribbean Hispanic families in at least five affected LOAD individuals, and further prioritized if observed in affected individuals in Caucasian families or showing segregation with LOAD and (2) variants observed in at least four affected LOAD individuals and no unaffected individuals from one Caribbean Hispanic family with CADD score \>15. We tested SNV association with LOAD using a GEE model to adjust for familial correlation. We found nominally significant association (*P* \< 0.05) for two SNVs each in *MYRF* and *ASRGL1,* respectively, (Table [2](#acn3537-tbl-0002){ref-type="table-wrap"}).

###### 

Results from follow‐up genotyping

                        NO APOE‐*ε*4[a](#acn3537-note-0003){ref-type="fn"}   APOE‐*ε*4[b](#acn3537-note-0004){ref-type="fn"}                                                      
  --------------------- ---------------------------------------------------- ------------------------------------------------- ------------- ----------- ---------- ------------- ------------
  1‐207680070‐C‐T       0.13                                                 0.21                                              5.2E‐01       0.15        0.21       4.6E‐01       CR1
  1‐207741237‐C‐T       1.61                                                 0.99                                              1.0E‐01       1.60        0.96       9.6E‐02       CR1
  7‐29035428‐C‐T        0.82                                                 0.44                                              6.3E‐02       0.80        0.43       6.2E‐02       CPVL
  7‐30876316‐C‐T        −0.58                                                0.42                                              1.7E‐01       −0.50       0.41       2.3E‐01       FAM188B
  7‐31682771‐C‐T        0.87                                                 1.25                                              4.9E‐01       0.86        1.26       4.9E‐01       CCDC129
  **7‐91630531‐C‐T**    **1.75**                                             **0.86**                                          **4.1E‐02**   **1.84**    **0.88**   **3.8E‐02**   **AKAP9**
  7‐91667736‐A‐G        0.35                                                 0.35                                              3.2E‐01       0.35        0.38       3.5E‐01       AKAP9
  7‐143091417‐C‐T       0.18                                                 0.68                                              8.0E‐01       0.19        0.67       7.7E‐01       EPHA1
  11‐60703423‐G‐A       0.06                                                 0.45                                              8.9E‐01       0.00        0.43       1.0E+00       TMEM132A
  11‐61015721‐G‐A       0.93                                                 0.54                                              8.5E‐02       0.81        0.54       1.3E‐01       PGA5
  11‐61120560‐G‐A       ‐0.08                                                0.58                                              8.9E‐01       ‐0.07       0.57       9.0E‐01       CYB561A3
  11‐61250246‐G‐A       0.10                                                 0.50                                              8.4E‐01       ‐0.02       0.47       9.6E‐01       PPP1R32
  **11‐61546888‐G‐A**   **‐0.55**                                            **0.26**                                          **3.8E‐02**   **‐0.49**   **0.26**   **5.9E‐02**   **MYRF**
  11‐62286666‐C‐T       0.72                                                 0.73                                              3.2E‐01       0.75        0.75       3.2E‐01       AHNAK
  **11‐62343562‐G‐C**   **1.09**                                             **0.50**                                          **2.8E‐02**   **0.96**    **0.51**   **5.9E‐02**   **ASRGL1**
  11‐62344743‐C‐T       0.72                                                 0.73                                              3.2E‐01       0.75        0.75       3.2E‐01       MIR3654
  11‐62400108‐G‐A       ‐0.31                                                0.36                                              4.0E‐01       ‐0.26       0.36       4.7E‐01       GANAB
  11‐62886345‐G‐A       0.21                                                 0.54                                              6.9E‐01       0.24        0.54       6.6E‐01       SLC3A2
  14‐93142861‐T‐C       0.29                                                 0.42                                              5.0E‐01       0.31        0.42       4.6E‐01       RIN3
  19‐1057919‐C‐T        0.62                                                 0.70                                              3.8E‐01       0.58        0.67       3.9E‐01       ABCA7

Model‐ LOAD \~ Gene + Age + Sex + proportion of African ancestry + proportion of Native American Ancestry + First ten principal components.

Model‐ LOAD \~ Gene + Age + Sex + number of APOE *ε*4 alleles + proportion of African ancestry + proportion of Native American Ancestry + First ten principal components. (nominally significant variants are highlighted in bold).
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Segregation of variants in established GWAS loci {#acn3537-sec-0021}
------------------------------------------------

We evaluated the segregation with LOAD of the 147 observed rare functional variants in 30 candidate genes implicated in LOAD by GWAS,[4](#acn3537-bib-0004){ref-type="ref"}, [5](#acn3537-bib-0005){ref-type="ref"} next‐generation sequencing or associated with early‐onset Alzheimer\'s disease. Sixteen of these variants were segregating in at least one family (Table [S3](#acn3537-sup-0002){ref-type="supplementary-material"}). Remarkably, five missense variants in *AKAP9* segregated with LOAD status in one or more families, p.R434W (Figs. [2](#acn3537-fig-0002){ref-type="fig"} and [3](#acn3537-fig-0003){ref-type="fig"}, Tables [S9](#acn3537-sup-0002){ref-type="supplementary-material"} and [S10](#acn3537-sup-0002){ref-type="supplementary-material"}) and p.I1448V (Fig. [S1](#acn3537-sup-0001){ref-type="supplementary-material"}) were subsequently genotyped in the all members of these families, and in an additional 48 families and an independent case--control set to determine complete segregation and test association with LOAD. We also genotyped two missense variants in *CR1* and one variant each, from *EPHA1*,*RIN3,* and *ABCA7* (Table [2](#acn3537-tbl-0002){ref-type="table-wrap"}) and used GEE adjusting for familial correlation. p.R434W was nominally associated with LOAD adjusting for age and sex (OR = 5.77; 95% confidence interval \[CI\] 1.07--30.9), *P* = 0.041) and *APOE‐ε4* (OR = 6.3; CI: 1.11--35.54, *P* = 0.038). p.R434W also segregated with LOAD status in two large families (Fig. [2](#acn3537-fig-0002){ref-type="fig"}). p.R434W was predicted to be damaging by SIFT and Polyphen and had a highly deleterious CADD score of 32. Previously implicated variants in *AKAP9* [40](#acn3537-bib-0040){ref-type="ref"} (rs144662445 and rs149979685) were each observed in one LOAD patient.

![Segregation pattern of *AKAP9* p.R434W in family 285 (Refer to Table [S8](#acn3537-sup-0002){ref-type="supplementary-material"} for conversion for EFIGA to ADSP ids).](ACN3-5-406-g002){#acn3537-fig-0002}

![Segregation pattern of *AKAP9* p.R434W in family 348 (Refer to Table S9 for conversion for EFIGA to ADSP ids).](ACN3-5-406-g003){#acn3537-fig-0003}

F‐SKAT gene based tests {#acn3537-sec-0022}
-----------------------

Nominal association was found for *CR1* (*P* = 0.049), *SLC24A4* (*P* = 0.040) and *BIN1* (*P* = 0.0098). *CR1* and S*LC24A4* were also significant in replication study of the Caucasian families (*P* = 0.040 and 0.002, respectively). (Table [3](#acn3537-tbl-0003){ref-type="table-wrap"}). However, only rare variants in *BIN1* (*P* = 0.026) remained significant after adjusting for the significant GWAS‐SNP that was previously associated with LOAD (Table [4](#acn3537-tbl-0004){ref-type="table-wrap"}).

###### 

F‐SKAT analyses of AD candidate GWAS loci

  GENE          N_LOF   No APOE[a](#acn3537-note-0005){ref-type="fn"}   APOE[b](#acn3537-note-0006){ref-type="fn"}
  ------------- ------- ----------------------------------------------- --------------------------------------------
  ABCA7         12      0.6655                                          0.7486
  AKAP9         9       0.6659                                          0.5895
  **BIN1**      **3**   **0.0098**                                      **0.0139**
  CASS4         2       0.3814                                          0.3871
  CIT           6       0.4767                                          0.5128
  **CR1**       **9**   **0.0490**                                      0.0830
  DSG2          5       0.4623                                          0.3587
  EPHA1         3       0.8159                                          0.8659
  FRMD4A        2       0.1807                                          0.1418
  INPP5D        4       0.5328                                          0.6067
  MAPT          5       0.7163                                          0.7605
  PSEN1         2       0.5914                                          0.7302
  RIN3          5       0.8367                                          0.8526
  **SLC24A4**   **3**   **0.0433**                                      **0.0505**
  SORL1         3       0.4285                                          0.4552
  TREM2         2       0.9846                                          0.9619

Model‐ LOAD \~ Gene + Age + Sex + proportion of African ancestry + proportion of Native American Ancestry + First ten principal components.

Model‐ LOAD \~ Gene + Age + Sex + number of APOE *ε*4 alleles + proportion of African ancestry + proportion of Native American Ancestry + First ten principal components.
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###### 

Results from FSKAT gene‐based analyses of all the genes within 1 MB of the AD loci implicated in the Lambert et al. report

  GENE       Chr   NO ADJUSTMENT FOR IGAP SNP[a](#acn3537-note-0007){ref-type="fn"}   ADJUSTING FOR IGAP SNP[b](#acn3537-note-0008){ref-type="fn"}   Top IGAP SNP   Nearest Gene                                      
  ---------- ----- ------------------------------------------------------------------ -------------------------------------------------------------- -------------- -------------- ---------- ---------- ------------ ----------
  MSH5       6     5                                                                  1.77E‐03                                                       0.00246474     5              1.81E‐03   2.61E‐03   rs9271192    HLA‐DRB5
  HLA‐DQA2   6     3                                                                  7.37E‐03                                                       6.50E‐03       3              6.64E‐03   6.01E‐03   rs9271192    HLA‐DRB5
  CYP3A43    7     6                                                                  5.69E‐03                                                       4.09E‐03       6              6.92E‐03   5.09E‐05   rs1476679    ZCWPW1
  TAF6       7     4                                                                  3.97E‐02                                                       3.11E‐02       4              1.44E‐02   1.67E‐04   rs1476679    ZCWPW1
  MAP3K2     2     3                                                                  1.56E‐02                                                       1.48E‐02       3              1.46E‐02   1.28E‐02   rs6733839    BIN1
  ZSCAN21    7     2                                                                  8.40E‐02                                                       1.06E‐01       2              1.80E‐02   4.10E‐03   rs1476679    ZCWPW1
  BIN1       2     4                                                                  2.77E‐02                                                       3.36E‐02       4              2.59E‐02   2.88E‐02   rs6733839    BIN1
  CHGA       14    4                                                                  3.39E‐02                                                       3.31E‐02       4              3.46E‐02   3.56E‐02   rs10498633   SLC24A4
  NAT16      7     2                                                                  7.30E‐02                                                       8.31E‐02       2              4.55E‐02   1.05E‐01   rs1476679    ZCWPW1
  LGMN       14    4                                                                  5.24E‐02                                                       2.74E‐02       4              4.70E‐02   2.29E‐02   rs10498633   SLC24A4
  TNXB       6     25                                                                 4.79E‐02                                                       5.19E‐02       25             4.91E‐02   5.38E‐02   rs9271192    HLA‐DRB5
  TFR2       7     6                                                                  1.04E‐01                                                       8.82E‐02       6              1.12E‐01   1.14E‐02   rs1476679    ZCWPW1

Model‐ LOAD \~ Gene + Age + Sex + proportion of African ancestry + proportion of Native American Ancestry + First ten principal components (without and without APOE *ε*4 adjustment).

Model‐ LOAD \~ Gene + Age + Sex + number of APOE *ε*4 alleles + proportion of African ancestry + proportion of Native American Ancestry + First ten principal components + Corresponding IGAP SNP (without and without APOE *ε*4 adjustment).
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As described in Table [4](#acn3537-tbl-0004){ref-type="table-wrap"}, the strongest LOAD associations after adjusting for the effect of the corresponding common variants were found in genes located in three loci: *HLA‐DRB5*,*ZCWPW1* and *BIN1*. *MSH5* (*P* = 0.0026) and *HLA‐DQA2* (*P* = 0.006) located in *HLA‐DRB5* region, and *CYP3A43* gene (5.09E‐05) located in *ZCWPW1* region were significantly associated with LOAD. *LGMN* in the *SLC24A4* region was modestly associated with LOAD in a model adjusted for *APOE* dosage (*P* = 0.033).

Discussion {#acn3537-sec-0023}
==========

A variant in *AKAP9,* (p.R434W), a gene previously associated with LOAD in a case--control study among African Americans,[40](#acn3537-bib-0040){ref-type="ref"} segregated in two large families and was nominally associated with LOAD, with fivefold increased risk adjusted for age, sex, and *APOE‐ε4*. The two different variants in *AKAP9* were previously identified, were considered rare in populations African‐descent, and were not present in European‐descent or East Asian‐descent individuals in the 1000 Genomes database. *AKAP9* is located on chromosome 7q21--22, and it encodes a member of the A kinase anchoring protein (*AKAP*) family. The A‐kinase anchor proteins (*AKAPs*) are structurally diverse proteins that bind to the regulatory subunits of protein kinase A (*PKA*), confining the holoenzyme to discrete locations within the cell. Alternate splicing of this gene results in at least two isoforms that localize to the centrosome and the Golgi apparatus, and interact with numerous signaling proteins from multiple signal transduction pathways.[41](#acn3537-bib-0041){ref-type="ref"} *AKAP9* is also expressed in the cerebral cortex, hippocampus, and cerebellum, and is involved in the cytoskeletal attachment of NMDA receptors, important for controlling synaptic plasticity and memory function.[42](#acn3537-bib-0042){ref-type="ref"}

In addition, missense mutations in Myelin Gene Regulatory Factor (*MYRF)* and Asparaginase‐Like Protein 1 (*ASRGL1)* genes under linkage peak on chromosome 11q12.3 segregated completely in one LOAD family and tested nominally significant (*P* \< 0.05) in association with LOAD in follow‐up genotyping. The *MYRF* gene encodes a transcription factor that is required for central nervous system myelination and may regulate oligodendrocyte differentiation. It increases expression of genes that affect myelin production. Mutant huntingtin mice show progressive neurological symptoms and early death, as well as age‐dependent demyelination and reduced expression of myelin genes that are downstream of *MYRF*.[43](#acn3537-bib-0043){ref-type="ref"}A missense mutation in *ASRGL1* has been associated with autosomal recessive retinal degeneration,[44](#acn3537-bib-0044){ref-type="ref"} but it has not been previously related to Alzheimer\'s disease or neurodegenerative disorders. In patients with retinal degeneration, variants in *ASRGL1* are thought to be the cause of protein misfolding, intracellular mis‐routing and aggregation of misfolded proteins. It is expressed in brain, specifically in astrocytes and oligodendrocytes.[45](#acn3537-bib-0045){ref-type="ref"}

Examination of known LOAD genes (e.g., from large GWAS‐based meta‐analyses) confirmed the role of rare functional variation in *CR1* (*P* = 0.049), *BIN1* (*P* = 0.0098), and *SLC24A4* (*P* = 0.040). *CR1* encodes a transmembrane glycoprotein in the innate immune system. It is a receptor for the complement components C3b and C4b. It has been consistently identified as a risk factor in Alzheimer\'s disease.[3](#acn3537-bib-0003){ref-type="ref"}, [4](#acn3537-bib-0004){ref-type="ref"}, [46](#acn3537-bib-0046){ref-type="ref"} *BIN1* encodes the bridging integrator 1 gene, which has also been consistently associated with Alzheimer\'s disease in GWAS studies.[4](#acn3537-bib-0004){ref-type="ref"}, [47](#acn3537-bib-0047){ref-type="ref"} *BIN1* is present in neurons, oligodendrocytes and microglia, and its primary role is thought to be in endocytosis and trafficking in neurons and immune response in glia cells.[48](#acn3537-bib-0048){ref-type="ref"} *SLC24A4* is a solute carrier that has been associated with pigmentation traits in European populations. However, more relevant to LOAD is its association with blood pressure in African Americans, as LOAD may be influenced by vascular disease.[49](#acn3537-bib-0049){ref-type="ref"}

Of the genes identified within the 2 Mb region surrounding the previously identified GWAS loci from the IGAP study,[1](#acn3537-bib-0001){ref-type="ref"}, [2](#acn3537-bib-0002){ref-type="ref"}, [3](#acn3537-bib-0003){ref-type="ref"}, [4](#acn3537-bib-0004){ref-type="ref"}, [5](#acn3537-bib-0005){ref-type="ref"}, [6](#acn3537-bib-0006){ref-type="ref"} several were nominally significant. *CYP3A43* is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids, and are part of a cluster of cytochrome P450 genes on chromosome 7q21.1. *MSH5* encodes a member of the mutS family of proteins that are involved in DNA mismatch repair or meiotic recombination processes. Women with premature ovarian failure were found to carry a mutation in *MSH5* suggesting a role in meiotic recombination. Genetic variants in a gene within the major histocompatibility complex, *HLA‐DQA2*, were associated with LOAD in this study. However, this gene has low expression in brain and has been associated with multiple inflammatory disorders.

Family‐based WGS on previously localized linkage regions remains a particularly powerful strategy for causal variant identification. Several new disease susceptibility genes have been successfully identified using linkage analysis coupled with WGS, in complex phenotype disorders such as hearing impairment,[50](#acn3537-bib-0050){ref-type="ref"} familial goiters,[51](#acn3537-bib-0051){ref-type="ref"} and familial hypertension.[52](#acn3537-bib-0052){ref-type="ref"}

Taken together the results here imply that rare variants in multiple genes are likely to increase the risk of LOAD. Large families multiply affected by LOAD are extremely helpful in identifying novel rare variants even in genes previously investigated by other means. For example, loci identified by genome wide array studies have pointed to a large number of genes many of which have rare variants suggesting that these loci were in linkage disequilibrium with one or more of the mutations. How variants in these multiple genes lead to a common phenotype of LOAD needs to be investigated. However, investigations of gene functions may point to potential targets for new treatments or preventive measures.

Conflict of Interest {#acn3537-sec-0026}
====================

The authors have no conflicts of interest to disclose.

Supporting information
======================

###### 

**Data S1.** Methods.

**Figure S1.** Details of carriers of pV707I variant in TMEM132A in Caribbean Hispanic family 860.

###### 

Click here for additional data file.

###### 

**Table S1.** WGS rare exonic variants segrgating with LOAD in chromosome 7q14.3 linkage region.

**Table S2**. Interesting variants segregatating with affection status in Chr 11 Linkage region.

**Table S3**. Rare missense variants in candidate LOAD genes segregating with AD in Caribbean Hispanic families.

**Table S4.** Variant count across the chromosomes and linkage regions at each filtering step (corresponding to Fig. 1).

**Table S5.** Gene‐based test for variants sets that including variants with CADD\>30.

**Table S6.** Caribbean Hispanic families contributing to the linkage signals on chromosomes 7 and 11.

**Table S7**. Details of carriers of pv707I variant in TMEM132A.

**Table S8.** For family 284, individual and family IDs are displayed as EFIGSA IDs.

**Table S9**. For familiy 348, individual and family IDs are displayed as EFIGA IDs.

###### 

Click here for additional data file.

**EFIGA and WHICAP cohorts:** Data collection for this project was supported by the Genetic Studies of Alzheimer\'s disease in Caribbean Hispanics (Estudio familiar de la genética de la enfermedad de Alzheimer, also known as EFIGA) and the Washington Heights and Inwood Community Aging Project (WHICAP) funded by the National Institute on Aging (NIA) and by the National Institutes of Health (NIH) (5R37AG015473, RF1AG015473, R56AG051876, 1RF1AG054023). We acknowledge the EFIGA and WHICAP study participants and the research and support staff for their contributions to this study. **ADSP:** The Alzheimer\'s Disease Sequencing Project (ADSP) is comprised of two Alzheimer\'s Disease (AD) genetics consortia and three National Human Genome Research Institute (NHGRI) funded Large Scale Sequencing and Analysis Centers (LSAC). The two AD genetics consortia are the Alzheimer\'s Disease Genetics Consortium (ADGC) funded by NIA (U01 AG032984), and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) funded by NIA (R01 AG033193), the National Heart, Lung, and Blood Institute (NHLBI), other National Institute of Health (NIH) institutes and other foreign governmental and non‐governmental organizations. The Discovery Phase analysis of sequence data is supported through UF1AG047133 (to Drs. Schellenberg, Farrer, Pericak‐Vance, Mayeux, and Haines); U01AG049505 to Dr. Seshadri; U01AG049506 to Dr. Boerwinkle; U01AG049507 to Dr. Wijsman; and U01AG049508 to Dr. Goate and the Discovery Extension Phase analysis is supported through U01AG052411 to Dr. Goate and U01AG052410 to Dr. Pericak‐Vance. Data generation and harmonization in the Follow‐up Phases is supported by U54AG052427 (to Drs. Schellenberg and Wang).**Cohorts sequenced in ADSP:** The ADGC cohorts include: Adult Changes in Thought (ACT), the Alzheimer\'s Disease Centers (ADC), the Chicago Health and Aging Project (CHAP), the Memory and Aging Project (MAP), Mayo Clinic (MAYO), Mayo Parkinson\'s Disease controls, University of Miami, the Multi‐Institutional Research in Alzheimer\'s Genetic Epidemiology Study (MIRAGE), the National Cell Repository for Alzheimer\'s Disease (NCRAD), the National Institute on Aging Late Onset Alzheimer\'s Disease Family Study (NIA‐LOAD), the Religious Orders Study (ROS), the Texas Alzheimer\'s Research and Care Consortium (TARC), Vanderbilt University/Case Western Reserve University (VAN/CWRU), the Washington Heights‐Inwood Columbia Aging Project (WHICAP) and the Washington University Sequencing Project (WUSP), the Columbia University Hispanic‐ Estudio Familiar de Influencia Genetica de Alzheimer (EFIGA), the University of Toronto (UT), and Genetic Differences (GD**)**. The CHARGE cohorts, with funding provided by 5RC2HL102419 and HL105756, include the following: Atherosclerosis Risk in Communities (ARIC) Study which is carried out as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), Austrian Stroke Prevention Study (ASPS), Cardiovascular Health Study (CHS), Erasmus Rucphen Family Study (ERF), Framingham Heart Study (FHS), and Rotterdam Study (RS). CHS research was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629, R01AG15928, and R01AG20098 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS‐NHLBI.org. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The three LSACs are: the Human Genome Sequencing Center at the Baylor College of Medicine (U54 HG003273), the Broad Institute Genome Center (U54HG003067), and the Washington University Genome Institute (U54HG003079). **NCRAD and NIAGADS:** Biological samples and associated phenotypic data used in primary data analyses were stored at Study Investigators institutions, and at the National Cell Repository for Alzheimer\'s Disease (NCRAD, U24AG021886) at Indiana University funded by NIA. Associated Phenotypic Data used in primary and secondary data analyses were provided by Study Investigators, the NIA funded Alzheimer\'s Disease Centers (ADCs), and the National Alzheimer\'s Coordinating Center (NACC, U01AG016976) and the National Institute on Aging Genetics of Alzheimer\'s Disease Data Storage Site (NIAGADS, U24AG041689) at the University of Pennsylvania, funded by NIA, and at the Database for Genotypes and Phenotypes (dbGaP) funded by NIH. This research was supported in part by the Intramural Research Program of the National Institutes of health, National Library of Medicine. Contributors to the Genetic Analysis Data included Study Investigators on projects that were individually funded by NIA, and other NIH institutes, and by private U.S. organizations, or foreign governmental or nongovernmental organizations.

ADSP consortium members {#acn3537-sec-0025}
=======================

[**Baylor College of Medicine:**]{.ul} Michelle Bellair, Huyen Dinh, Harsha Doddapeneni, Shannon Dugan‐Perez, Adam English, Richard A. Gibbs, Yi Han, Jianhong Hu, Joy Jayaseelan, Divya Kalra, Ziad Khan, Viktoriya Korchina, Sandra Lee, Yue Liu, Xiuping Liu, Donna Muzny, Waleed Nasser, William Salerno, Jireh Santibanez, Evette Skinner, Simon White, Kim Worley, Yiming Zhu. [**Boston University:**]{.ul} Alexa Beiser, Yuning Chen, Jaeyoon Chung, L. Adrienne Cupples, Anita DeStefano, Josee Dupuis, John Farrell, Lindsay Farrer, Daniel Lancour, Honghuang Lin, Ching Ti Liu, Kathy Lunetta, Yiyi Ma, Devanshi Patel, Chloe Sarnowski, Claudia Satizabal, Sudha Seshadri, Fangui Jenny Sun, Xiaoling Zhang. [**Broad Institute**]{.ul} **:** Seung Hoan Choi, Eric Banks, Stacey Gabriel, Namrata Gupta. [**Case Western Reserve University**]{.ul} **:** William Bush, Mariusz Butkiewicz, Jonathan Haines, Sandra Smieszek, Yeunjoo Song. [**Columbia University**]{.ul} **:** Sandra Barral, Phillip L De Jager, Richard Mayeux, Christiane Reitz, Dolly Reyes, Giuseppe Tosto, Badri Vardarajan. [**Erasmus Medical University**]{.ul} **:** Shahzad Amad, Najaf Amin, M Afran Ikram, Sven van der Lee, Cornelia van Duijn, Ashley Vanderspek. [**Medical University Graz**]{.ul} **:** Helena Schmidt, Reinhold Schmidt; [**Mount Sinai School of Medicine**]{.ul} **:** Alison Goate, Manav Kapoor, Edoardo Marcora, Alan Renton; [**Indiana University**]{.ul} **:** Kelley Faber, Tatiana Foroud; [**National Center Biotechnology Information**]{.ul} **:** Michael Feolo,Adam Stine; [**National Institute on Aging**]{.ul} **:** Lenore J. Launer; [**Rush University**]{.ul} **:** David A. Bennett; [**Stanford University**]{.ul} **:** Li Charlie Xia; [**University of Miami**]{.ul} **:** Gary Beecham, Kara Hamilton‐Nelson, James Jaworski, Brian Kunkle, Eden Martin, Margaret Pericak‐Vance, Farid Rajabli, Michael Schmidt; [**University of Mississippi**]{.ul} **:** Thomas H. Mosley; [**University of Pennsylvania**]{.ul} **:** Laura Cantwell, Micah Childress, Yi‐Fan Chou, Rebecca Cweibel, Prabhakaran Gangadharan, Amanda Kuzma, Yuk Yee Leung, Han‐Jen Lin, John Malamon, Elisabeth Mlynarski, Adam Naj, Liming Qu, Gerard Schellenberg, Otto Valladares, Li‐San Wang, Weixin Wang, Nancy Zhang; [**University of Texas Houston**]{.ul} **:** Jennifer E. Below, Eric Boerwinkle, Jan Bressler, Myriam Fornage, Xueqiu Jian, Xiaoming Liu; [**University of Washington**]{.ul} **:** Joshua C. Bis, Elizabeth Blue, Lisa Brown, Tyler Day, Michael Dorschner, Andrea R. Horimoto, Rafael Nafikov, Alejandro Q. Nato Jr., Pat Navas, Hiep Nguyen, Bruce Psaty, Kenneth Rice, Mohamad Saad, Harkirat Sohi, Timothy Thornton, Debby Tsuang, Bowen Wang, Ellen Wijsman, Daniela Witten; [**Washington University**]{.ul} **:** Lucinda Antonacci‐Fulton, Elizabeth Appelbaum, Carlos Cruchaga, Robert S. Fulton, Daniel C. Koboldt, David E. Larson, Jason Waligorski, Richard K. Wilson.
